Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer

Archives of Internal Medicine

Volumn 166, Issue 4, 2006, Pages 465-471

  Shahinian, Vahakn B ^a,b   Kuo, Yong Fang ^a,b   Freeman, Jean L ^a,b   Goodwin, James S ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN;

ADJUSTMENT DISORDER; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION SYNDROME; ANOREXIA; ANXIETY DISORDER; ARTICLE; BRAIN DEGENERATION; CACHEXIA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEPRESSION; DIAGNOSTIC PROCEDURE; DRUG SURVEILLANCE PROGRAM; ENDOCRINE DISEASE; FATIGUE; HEALTH STATUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALAISE; MALE; MEDICARE; MEMORY DISORDER; OLIGOPHRENIA; PHYSICIAN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CARCINOMA; PSYCHOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SENILE DEMENTIA; SIDE EFFECT; SLEEP DISORDER; SURVIVAL RATE; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COGNITION DISORDERS; DEPRESSION; FATIGUE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SYNDROME;

EID: 33644590549     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/.465     Document Type: Article

References (39)

1. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002;60(suppl 3A):7-12.
2. Shahinian VB, Kuo Y-F, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for localized prostate cancer. Cancer. 2005;103:1615-1624.
3. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981-989.
4. Soloway MS. Timing of androgen deprivation for prostate cancer: benefits versus side effects - a patient-physician dialogue. Urology. 2002;60:735-737.
5. Milbank AJ, Dreicer R, Klein EA. Hormonal therapy for prostate cancer: primum non nocere. Urology. 2002;60:738-741.
6. Schroder FH. Endocrine treatment of prostate cancer - recent developments and the future, 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. BJU Int. 1999;83:161-170.
7. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61(suppl 1):32-38.
8. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
9. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol. 2004;14:177-183.
10. Rosenblatt DE, Mellow A. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract. 1995;8:317-320.
11. Freeman MP, Freeman SA. Treatment of leuprolide-induced depression with intramuscular testosterone: a case report. J Clin Psychiatry. 2003;64:341-343.
12. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology. 1996;48:800-804.
13. Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology. 2002;11:518-523.
14. Green HJ, Pakenham KI, Headley J, et al. Altered cognitive function in men treated for prostate cancer with luteinizing-hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002;90:427-432.
15. Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer. 1998;34:1670-1676.
16. McDermed J, Strum S, Scholz M. The androgen deprivation syndrome (ADS): the incidence and severity in prostate cancer (PC) patients (PTS) receiving hormone blockade (HB) [abstract]. Proc Am Soc Clin Oncol. 1998;17:315a.
17. Freedman A, Hahn G, Love N. Follow-up after therapy for prostate cancer. Postgrad Med. 1996;100:125-129, 133-34, 136.
18. Sunga AY, Eberl MM, Oeffinger KC, Hudson MM, Mahoney MC. Care of cancer survivors. Am Fam Physician. 2005;71:699-706, 713-714.
19. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist. 2003;8:474-487.
20. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-18.
21. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
23. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
24. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821-827.
25. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937-946.
26. Seidman SN, Walsh BT. Testosterone and depression in aging men. Am J Geriatr Psychiatry. 1999;7:18-33.
27. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61:162-167.
28. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 1998;48:157-161.
29. Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc. 2002;50:707-712.
30. Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57:80-88.
31. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599-603.
32. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261-4267.
33. Salminen E, Portin R, Korpela J, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer. 2003;89:971-976.
34. Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr. 2004;32:150-157.
35. Valentine AD, Meyers CA. Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer. 2001;92:1694-1698.
36. Leon FG, Ashton AK, D'Mello DA, et al. Depression and comorbid medical illness: therapeutic and diagnostic challenges. J Fam Pract. 2003; Dec(suppl):S19-S33.
37. Raj A. Depression in the elderly: tailoring medical therapy to their special needs. Postgrad Med. 2004;115:26-28, 37-42.
38. Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earler CC, Begg CN. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002;40(8 suppl):IV-62-68.
39. Davidson JRT, Melzer-Brady SE. The under recognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry. 1999;60(suppl 7):4-9.